Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 343

1.

Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole.

Dekker SJ, Dohmen F, Vermeulen NPE, Commandeur JNM.

Br J Pharmacol. 2019 Feb;176(3):466-477. doi: 10.1111/bph.14548. Epub 2018 Dec 26.

2.

Linking cytochrome P450 enzymes from Mycobacterium tuberculosis to their cognate ferredoxin partners.

Ortega Ugalde S, de Koning CP, Wallraven K, Bruyneel B, Vermeulen NPE, Grossmann TN, Bitter W, Commandeur JNM, Vos JC.

Appl Microbiol Biotechnol. 2018 Nov;102(21):9231-9242. doi: 10.1007/s00253-018-9299-4. Epub 2018 Aug 22.

3.

Acetaminophen reduces the protein levels of high affinity amino acid permeases and causes tryptophan depletion.

Huseinovic A, Dekker SJ, Boogaard B, Vermeulen NPE, Kooter JM, Vos JC.

Amino Acids. 2018 Oct;50(10):1377-1390. doi: 10.1007/s00726-018-2613-8. Epub 2018 Jul 5.

4.

A combined computational and experimental study on selective flucloxacillin hydroxylation by cytochrome P450 BM3 variants.

Luirink RA, Dekker SJ, Capoferri L, Janssen LFH, Kuiper CL, Ari ME, Vermeulen NPE, Vos JC, Commandeur JNM, Geerke DP.

J Inorg Biochem. 2018 Jul;184:115-122. doi: 10.1016/j.jinorgbio.2018.04.013. Epub 2018 Apr 24.

PMID:
29723739
5.

Glutathione S-Transferase P1 Protects Against Amodiaquine Quinoneimines-Induced Cytotoxicity but Does Not Prevent Activation of Endoplasmic Reticulum Stress in HepG2 Cells.

Zhang Y, den Braver-Sewradj SP, den Braver MW, Hiemstra S, Vermeulen NPE, van de Water B, Commandeur JNM, Vos JC.

Front Pharmacol. 2018 Apr 18;9:388. doi: 10.3389/fphar.2018.00388. eCollection 2018.

6.

High-performance liquid chromatography-based assay for glutathione transferase theta 2 activity: Application to characterize interindividual variability in human liver fractions.

Zhang Y, Wijaya L, Dekker SJ, Vermeulen NPE, Commandeur JNM.

J Pharm Biomed Anal. 2018 Jul 15;156:181-188. doi: 10.1016/j.jpba.2018.04.037. Epub 2018 Apr 23.

PMID:
29709785
7.

Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals.

den Braver-Sewradj SP, den Braver MW, van Dijk M, Zhang Y, Dekker SJ, Wijaya L, Vermeulen NPE, Richert L, Commandeur JNM, Vos JC.

Curr Drug Metab. 2018;19(4):370-381. doi: 10.2174/1389200219666180108160046.

PMID:
29318967
8.

Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.

den Braver-Sewradj SP, den Braver MW, Toorneman RM, van Leeuwen S, Zhang Y, Dekker SJ, Vermeulen NPE, Commandeur JNM, Vos JC.

Chem Res Toxicol. 2018 Feb 19;31(2):116-126. doi: 10.1021/acs.chemrestox.7b00289. Epub 2018 Jan 11.

9.

Drug toxicity profiling of a Saccharomyces cerevisiae deubiquitinase deletion panel shows that acetaminophen mimics tyrosine.

Huseinovic A, van Dijk M, Vermeulen NPE, van Leeuwen F, Kooter JM, Vos JC.

Toxicol In Vitro. 2018 Mar;47:259-268. doi: 10.1016/j.tiv.2017.12.007. Epub 2017 Dec 16.

10.

Engineering a self-sufficient Mycobacterium tuberculosis CYP130 by gene fusion with the reductase-domain of CYP102A1 from Bacillus megaterium.

Ortega Ugalde S, Luirink RA, Geerke DP, Vermeulen NPE, Bitter W, Commandeur JNM.

J Inorg Biochem. 2018 Mar;180:47-53. doi: 10.1016/j.jinorgbio.2017.12.003. Epub 2017 Dec 7.

PMID:
29232638
11.

Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism.

Lazarska KE, Dekker SJ, Vermeulen NPE, Commandeur JNM.

Toxicol Lett. 2018 Mar 1;284:70-78. doi: 10.1016/j.toxlet.2017.11.038. Epub 2017 Dec 2.

12.

eTOX ALLIES: an automated pipeLine for linear interaction energy-based simulations.

Capoferri L, van Dijk M, Rustenburg AS, Wassenaar TA, Kooi DP, Rifai EA, Vermeulen NPE, Geerke DP.

J Cheminform. 2017 Nov 21;9(1):58. doi: 10.1186/s13321-017-0243-x.

13.

Legacy data sharing to improve drug safety assessment: the eTOX project.

Sanz F, Pognan F, Steger-Hartmann T, Díaz C; eTOX, Cases M, Pastor M, Marc P, Wichard J, Briggs K, Watson DK, Kleinöder T, Yang C, Amberg A, Beaumont M, Brookes AJ, Brunak S, Cronin MTD, Ecker GF, Escher S, Greene N, Guzmán A, Hersey A, Jacques P, Lammens L, Mestres J, Muster W, Northeved H, Pinches M, Saiz J, Sajot N, Valencia A, van der Lei J, Vermeulen NPE, Vock E, Wolber G, Zamora I.

Nat Rev Drug Discov. 2017 Dec;16(12):811-812. doi: 10.1038/nrd.2017.177. Epub 2017 Oct 13.

PMID:
29026211
14.

Binding free energy predictions of farnesoid X receptor (FXR) agonists using a linear interaction energy (LIE) approach with reliability estimation: application to the D3R Grand Challenge 2.

Rifai EA, van Dijk M, Vermeulen NPE, Geerke DP.

J Comput Aided Mol Des. 2018 Jan;32(1):239-249. doi: 10.1007/s10822-017-0055-0. Epub 2017 Sep 9.

15.

Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.

den Braver-Sewradj SP, den Braver MW, Baze A, Decorde J, Fonsi M, Bachellier P, Vermeulen NPE, Commandeur JNM, Richert L, Vos JC.

Eur J Pharm Sci. 2017 Nov 15;109:96-110. doi: 10.1016/j.ejps.2017.07.032. Epub 2017 Aug 1.

PMID:
28778465
16.

Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors.

van Dijk M, Ter Laak AM, Wichard JD, Capoferri L, Vermeulen NPE, Geerke DP.

J Chem Inf Model. 2017 Sep 25;57(9):2294-2308. doi: 10.1021/acs.jcim.7b00222. Epub 2017 Aug 23.

17.

Human glutathione S-transferases- and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: Possible implications for susceptibility to amodiaquine-induced liver toxicity.

Zhang Y, den Braver-Sewradj SP, Vos JC, Vermeulen NPE, Commandeur JNM.

Toxicol Lett. 2017 Jun 5;275:83-91. doi: 10.1016/j.toxlet.2017.05.003. Epub 2017 May 3.

PMID:
28478157
18.

The effect of acetaminophen on ubiquitin homeostasis in Saccharomyces cerevisiae.

Huseinovic A, van Leeuwen JS, van Welsem T, Stulemeijer I, van Leeuwen F, Vermeulen NP, Kooter JM, Vos JC.

PLoS One. 2017 Mar 14;12(3):e0173573. doi: 10.1371/journal.pone.0173573. eCollection 2017.

19.

Generic method for the absolute quantification of glutathione S-conjugates: Application to the conjugates of acetaminophen, clozapine and diclofenac.

den Braver MW, Vermeulen NPE, Commandeur JNM.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Mar 1;1046:185-194. doi: 10.1016/j.jchromb.2017.02.004. Epub 2017 Feb 6.

PMID:
28189104
20.

Different Reactive Metabolites of Nevirapine Require Distinct Glutathione S-Transferase Isoforms for Bioinactivation.

Dekker SJ, Zhang Y, Vos JC, Vermeulen NP, Commandeur JN.

Chem Res Toxicol. 2016 Dec 19;29(12):2136-2144. Epub 2016 Nov 28.

PMID:
27989146
21.

Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine.

Zhang Y, Vermeulen NP, Commandeur JN.

Br J Clin Pharmacol. 2017 Mar;83(3):572-583. doi: 10.1111/bcp.13148. Epub 2016 Nov 16.

22.

Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.

Dragovic S, Vermeulen NP, Gerets HH, Hewitt PG, Ingelman-Sundberg M, Park BK, Juhila S, Snoeys J, Weaver RJ.

Arch Toxicol. 2016 Dec;90(12):2979-3003. Epub 2016 Sep 22. Review.

23.

Response to “The Path Forward on Endocrine Disruptors Requires Focus”.

Autrup H, Barile F, Blaauboer BJ, Degen GH, Dekant W, Dietrich D, Domingo JL, Gori GB, Greim H, Hengstler JG, Kacew S, Marquardt H, Pelkonen O, Savolainen K, Vermeulen NP.

Toxicol Sci. 2016 Feb;149(2):273-4. No abstract available.

PMID:
27213197
24.

Simulation of interindividual differences in inactivation of reactive para-benzoquinone imine metabolites of diclofenac by glutathione S-transferases in human liver cytosol.

den Braver MW, Zhang Y, Venkataraman H, Vermeulen NP, Commandeur JN.

Toxicol Lett. 2016 Jul 25;255:52-62. doi: 10.1016/j.toxlet.2016.05.015. Epub 2016 May 13.

PMID:
27183920
25.

Characterization of cytochrome P450 isoforms involved in sequential two-step bioactivation of diclofenac to reactive p-benzoquinone imines.

den Braver MW, den Braver-Sewradj SP, Vermeulen NP, Commandeur JN.

Toxicol Lett. 2016 Jun 24;253:46-54. doi: 10.1016/j.toxlet.2016.04.022. Epub 2016 Apr 26.

PMID:
27130197
26.

Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer.

den Braver-Sewradj SP, den Braver MW, Vermeulen NP, Commandeur JN, Richert L, Vos JC.

Toxicol In Vitro. 2016 Jun;33:71-9. doi: 10.1016/j.tiv.2016.02.013. Epub 2016 Feb 26.

PMID:
26921663
27.

Improving the iterative Linear Interaction Energy approach using automated recognition of configurational transitions.

Vosmeer CR, Kooi DP, Capoferri L, Terpstra MM, Vermeulen NP, Geerke DP.

J Mol Model. 2016 Jan;22(1):31. doi: 10.1007/s00894-015-2883-y. Epub 2016 Jan 12.

28.

Insights into regioselective metabolism of mefenamic acid by cytochrome P450 BM3 mutants through crystallography, docking, molecular dynamics, and free energy calculations.

Capoferri L, Leth R, ter Haar E, Mohanty AK, Grootenhuis PD, Vottero E, Commandeur JN, Vermeulen NP, Jørgensen FS, Olsen L, Geerke DP.

Proteins. 2016 Mar;84(3):383-96. doi: 10.1002/prot.24985. Epub 2016 Feb 3.

PMID:
26757175
29.

Application of a cocktail approach to screen cytochrome P450 BM3 libraries for metabolic activity and diversity.

Reinen J, Postma G, Tump C, Bloemberg T, Engel J, Vermeulen NP, Commandeur JN, Honing M.

Anal Bioanal Chem. 2016 Feb;408(5):1425-43. doi: 10.1007/s00216-015-9241-x. Epub 2016 Jan 11.

30.

Linear Interaction Energy Based Prediction of Cytochrome P450 1A2 Binding Affinities with Reliability Estimation.

Capoferri L, Verkade-Vreeker MC, Buitenhuis D, Commandeur JN, Pastor M, Vermeulen NP, Geerke DP.

PLoS One. 2015 Nov 9;10(11):e0142232. doi: 10.1371/journal.pone.0142232. eCollection 2015.

31.

Application of a Continuous-Flow Bioassay to Investigate the Organic Solvent Tolerability of Cytochrome P450 BM3 Mutants.

Reinen J, van Hemert D, Vermeulen NP, Commandeur JN.

J Biomol Screen. 2015 Dec;20(10):1246-55. doi: 10.1177/1087057115607183. Epub 2015 Sep 22.

PMID:
26396180
32.

Mass spectrometric identification of isocyanate-induced modifications of keratins in human skin.

Hulst AG, Verstappen DR, van der Riet-Van Oeveren D, Vermeulen NP, Noort D.

Chem Biol Interact. 2015 Jul 25;237:141-50. doi: 10.1016/j.cbi.2015.06.008. Epub 2015 Jun 10.

PMID:
26070416
33.

Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System.

Autrup H, Barile FA, Blaauboer BJ, Degen GH, Dekant W, Dietrich D, Domingo JL, Gori GB, Greim H, Hengstler JG, Kacew S, Marquardt H, Pelkonen O, Savolainen K, Vermeulen NP.

Toxicol Sci. 2015 Jul;146(1):11-5. doi: 10.1093/toxsci/kfv082. Epub 2015 May 30.

PMID:
26026993
34.

Integrative Modeling Strategies for Predicting Drug Toxicities at the eTOX Project.

Sanz F, Carrió P, López O, Capoferri L, Kooi DP, Vermeulen NP, Geerke DP, Montanari F, Ecker GF, Schwab CH, Kleinöder T, Magdziarz T, Pastor M.

Mol Inform. 2015 Jun;34(6-7):477-84. doi: 10.1002/minf.201400193. Epub 2015 Jun 11.

PMID:
27490391
35.

Characterization of human cytochrome P450s involved in the bioactivation of tri-ortho-cresyl phosphate (ToCP).

Reinen J, Nematollahi L, Fidder A, Vermeulen NP, Noort D, Commandeur JN.

Chem Res Toxicol. 2015 Apr 20;28(4):711-21. doi: 10.1021/tx500490v. Epub 2015 Mar 2.

PMID:
25706813
36.

Mini-dialysis tubes as tools to prepare drug-protein adducts of P450-dependent reactive drug metabolites.

Boerma JS, Elias NS, Vermeulen NP, Commandeur JN.

J Pharm Biomed Anal. 2015 Jan 25;103:17-25. doi: 10.1016/j.jpba.2014.10.025. Epub 2014 Oct 31.

PMID:
25462116
37.

Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.

Vredenburg G, den Braver-Sewradj S, van Vugt-Lussenburg BM, Vermeulen NP, Commandeur JN, Vos JC.

Toxicol Lett. 2015 Jan 5;232(1):182-92. doi: 10.1016/j.toxlet.2014.11.005. Epub 2014 Nov 6.

PMID:
25448283
38.

Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases.

Venkataraman H, den Braver MW, Vermeulen NP, Commandeur JN.

Chem Res Toxicol. 2014 Dec 15;27(12):2071-81. doi: 10.1021/tx500288b. Epub 2014 Nov 18.

PMID:
25372302
40.

Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.

Venkataraman H, Verkade-Vreeker MC, Capoferri L, Geerke DP, Vermeulen NP, Commandeur JN.

Bioorg Med Chem. 2014 Oct 15;22(20):5613-20. doi: 10.1016/j.bmc.2014.06.022. Epub 2014 Jun 19.

PMID:
24999003
41.

Human NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated inactivation of reactive quinoneimine metabolites of diclofenac and mefenamic acid.

Vredenburg G, Elias NS, Venkataraman H, Hendriks DF, Vermeulen NP, Commandeur JN, Vos JC.

Chem Res Toxicol. 2014 Apr 21;27(4):576-86. doi: 10.1021/tx400431k. Epub 2014 Feb 26.

PMID:
24552538
42.

Towards automated binding affinity prediction using an iterative linear interaction energy approach.

Vosmeer CR, Pool R, Van Stee MF, Peric-Hassler L, Vermeulen NP, Geerke DP.

Int J Mol Sci. 2014 Jan 9;15(1):798-816. doi: 10.3390/ijms15010798.

43.

One-electron oxidation of diclofenac by human cytochrome P450s as a potential bioactivation mechanism for formation of 2'-(glutathion-S-yl)-deschloro-diclofenac.

Boerma JS, Vermeulen NP, Commandeur JN.

Chem Biol Interact. 2014 Jan 25;207:32-40. doi: 10.1016/j.cbi.2013.11.001. Epub 2013 Nov 15.

PMID:
24246759
44.

Effect of human glutathione S-transferase hGSTP1-1 polymorphism on the detoxification of reactive metabolites of clozapine, diclofenac and acetaminophen.

Dragovic S, Venkataraman H, Begheijn S, Vermeulen NP, Commandeur JN.

Toxicol Lett. 2014 Jan 13;224(2):272-81. doi: 10.1016/j.toxlet.2013.10.023. Epub 2013 Oct 31.

PMID:
24185126
45.

Effect of human glutathione S-transferases on glutathione-dependent inactivation of cytochrome P450-dependent reactive intermediates of diclofenac.

Dragovic S, Boerma JS, Vermeulen NP, Commandeur JN.

Chem Res Toxicol. 2013 Nov 18;26(11):1632-41. doi: 10.1021/tx400204d. Epub 2013 Nov 5.

PMID:
24083800
46.

Reconstitution of the interplay between cytochrome P450 and human glutathione S-transferases in clozapine metabolism in yeast.

Vredenburg G, Vassell KP, Commandeur JN, Vermeulen NP, Vos JC.

Toxicol Lett. 2013 Oct 9;222(3):247-56. doi: 10.1016/j.toxlet.2013.07.023. Epub 2013 Aug 2.

PMID:
23916688
47.

Characterization of human cytochrome P450s involved in the bioactivation of clozapine.

Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN.

Drug Metab Dispos. 2013 Mar;41(3):651-8. doi: 10.1124/dmd.112.050484. Epub 2013 Jan 7. Erratum in: Drug Metab Dispos. 2013 Apr;41(4):923.

PMID:
23297297
48.

Urinary lipid and protein oxidation products upon halothane, isoflurane, or sevoflurane anesthesia in humans: potential biomarkers for a subclinical nephrotoxicity.

Orhan H, Sahin A, Sahin G, Aypar U, Vermeulen NP.

Biomarkers. 2013 Feb;18(1):73-81. doi: 10.3109/1354750X.2012.737026. Epub 2012 Nov 9.

PMID:
23136842
49.

Mass spectrometric characterization of protein adducts of multiple P450-dependent reactive intermediates of diclofenac to human glutathione-S-transferase P1-1.

Boerma JS, Dragovic S, Vermeulen NP, Commandeur JN.

Chem Res Toxicol. 2012 Nov 19;25(11):2532-41. doi: 10.1021/tx300334w. Epub 2012 Oct 10.

PMID:
22998212
50.

Yeast as a humanized model organism for biotransformation-related toxicity.

van Leeuwen JS, Vermeulen NP, Chris Vos J.

Curr Drug Metab. 2012 Dec;13(10):1464-75. Review.

PMID:
22935071

Supplemental Content

Loading ...
Support Center